Commit and Melanodermic leukodystrophy - a phase IV clinical study of FDA data

Summary:

We study 5,235 people who take Commit (nicotine polacrilex) or have Melanodermic leukodystrophy. No report of Melanodermic leukodystrophy is found in people who take Commit.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Commit?

Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,842 Commit users. Check the latest studies of Commit.

What is Melanodermic Leukodystrophy?

Melanodermic leukodystrophy (disorder of very-long-chain fatty acid (vlcf) metabolism that leads to progressive neurological and adrenal dysfunction from accumulation of vlcf in the nervous system, adrenal glands, and testes) is found to be associated with 10 drugs and 18 conditions by eHealthMe. Check the latest studies of Melanodermic leukodystrophy.

On Jun, 19, 2026

No report is found.

Do you take Commit and have Melanodermic leukodystrophy?

- Check whether Melanodermic leukodystrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Commit:

Commit (4,842 reports)

Browse all side effects of Commit:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Melanodermic leukodystrophy:

Melanodermic leukodystrophy

Browse all the conditions that are associated with Melanodermic leukodystrophy:

Melanodermic leukodystrophy

How the study uses the data?

The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.